Melioidosis, Singapore, 2003–2014

Long Pang, Patrick N.A. Harris, Rachel L. Seiler, Peng Lim Ooi, Jeffrey Cutter, Kee Tai Goh, Alex R. Cook, Dale Fisher, Louis Yi Ann Chai

In contrast with northern Australia and Thailand, in Singapore the incidence of melioidosis and co-incidence of melioidosis and pneumonia have declined. *Burkholderia pseudomallei* deep abscesses increased 20.4% during 2003–2014. These trends could not be explained by the environmental and climatic factors conventionally ascribed to melioidosis.

Melioidosis is endemic throughout Southeast Asia and northern Australia. Caused by the environmental gram-negative bacillus *Burkholderia pseudomallei*, melioidosis can manifest as bacteremia, abscesses, or pneumonia. A case-fatality rate of >50% has been reported (1).

Australia, Thailand, and Singapore have the most reported cases of melioidosis worldwide (2). The geographic, climatic, and infrastructural landscapes of these 3 countries differ vastly. The population demographics and ease of accessibility to healthcare also differ and may influence disease manifestations and outcomes. Epidemiologic case studies from Singapore are limited (3). We describe the latest epidemiologic findings based on national melioidosis surveillance data for 2003–2014.

The Study
Melioidosis is a notifiable condition in Singapore. The laboratory and clinical criteria for notification are defined by the Ministry of Health, Singapore (4). Our study comprised all cases reported by medical practitioners and microbiology laboratories during 2003–2014. Public health officers collected demographic and clinical details of persons with notified cases using a standardized template. The data were extracted from the Ministry’s Communicable Disease Surveillance system (5). We used a Poisson regression model, offset for population, to fit the annual melioidosis incidence to measure overall trend. A binomial generalized linear model with identity link was used to quantify temporal changes in the absolute proportion of melioidosis cases having each comorbidity. We conducted a binomial test of whether the prevalence of comorbidities equaled that of the general population; the latter was derived from the last published National Health Survey 2010 (http://www.moh.gov.sg/content/moh_web/home/Publications/Reports/2011/national_health_survey2010.html) for persons 50–59 years of age (for diabetes and hypertension) and 40–54 years of age (for renal impairment). Analyses were performed with R Statistical Software version 3.3.1 (https://www.r-project.org/).

During the 12 years studied, notifications were received for 614 (range 31–96 annually) melioidosis cases (Table). The mean age of patients was 51.4 years; most (84.0%) patients were males. Most (72.1%) cases occurred in patients ≥45 years of age. The overall incidence of melioidosis was 1.1 per 100,000 population; incidence was highest among Malay and Indian populations (2.4 and 2.1/100,000, respectively). The most common manifestations of melioidosis were *B. pseudomallei* bacteremia (60.3%), abscesses (40.7%), and pneumonia (33.1%). Among the comorbidities reported (Table), diabetes (56.7%) and renal impairment (15.3%) had significantly higher prevalence among persons with melioidosis than among the general population of approximately the same age (19.3%, p<0.001 for diabetes; 2.0%, p<0.001 for renal impairment). In contrast, hypertension prevalence was consistent between melioidosis patients and the general population (35.5% vs. 31.9%; p = 0.057).

During 2003–2014, melioidosis incidence decreased by 10% annually (incidence rate ratio 0.900; 95% CI 0.878–0.923; p<0.001). The overall death rate was 18.4% and decreased by 12.3% annually (incidence rate ratio, 0.877; 95% CI 0.826–0.931; p<0.001) (Figure 1). Among melioidosis patients, there was a borderline declining trend in *B. pseudomallei* bacteremia cases annually (absolute risk reduction [ARR] 1.1%; 95% CI −2.3% to 0.1%; p = 0.076). However, the death rate for bacteremic patients did not change (ARR 0.4%; 95% CI −1.2% to 0.4%; p = 0.355) (Figure 2, panel A). In contrast, melioidosis patients with pneumonia decreased from a peak of 56 cases in 2004 to no cases in 2014 (ARR 5.1%; 95% CI −5.6% to −4.6%; p<0.001), accompanied by an ARR of 1.5% in mortality annually (95% CI −1.9% to −1.1%; p<0.001) or


DOI: https://doi.org/10.3201/eid2401.161449

1These authors contributed equally to this article.
abscesses—after rainfall—after rainfall—after rainfall

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 24, No. 1, January 2018


Figure 1. Annual incidence of melioidosis per 100,000 persons, Singapore, 2003–2014.
Soil, in particular anthrosol and acrisol soil, encountered in irrigated agriculture, has been suggested as a likely reservoir for *B. pseudomallei* (10). Consequently, urbanization leading to reduction of agricultural or rural land areas ought to align with a lower incidence of melioidosis. However, the developed island state of Singapore already had reached 100% urbanization by the early 1990s (11); thus, urbanization could not have been the primary factor for this decreasing incidence after 2003.

Conversely, water sanitization, storm/rainwater drainage, and flood reduction have remained a major focus of ongoing infrastructural improvements of the Singapore government through the 2000s to now. The national water strategy entails a complex system encompassing optimized drainage and collection, followed by water treatment intended for consumption and use. Flood risk is managed through design and implementation of state-of-the-art water drainage systems and flood-protection measures for public infrastructures (12). Together with a national flood alert response plan, these measures potentially minimize direct rain or contaminated water exposure and aerosol inhalation risk; thus, they are plausible factors to account for the overall melioidosis and pneumonia case reductions, but further study is needed to investigate this possibility.

**Figure 2.** Melioidosis trends, Singapore, 2003–2014. A) Annual incidence of *Burkholderia pseudomallei* bacteremia and bacteremia-related deaths per 100 melioidosis cases. B) Annual incidence of melioidosis patients with pneumonia and pneumonia-related death per 100 melioidosis patients. C) Annual incidence of *B. pseudomallei* abscesses per 100 melioidosis patients. Local abscesses as per superficial or cutaneous, and deep abscess as per deep organ (primarily liver, spleen and prostate). D) Annual incidence of diabetes and diabetes-related death per 100 melioidosis patients.
We did not anticipate the 20.4% increase of *B. pseudomallei* deep organ abscesses during the study period. We theorized that it might partly be explained by compromised host immunity to *B. pseudomallei*, attributable to the progressively higher prevalence of diabetes in Singapore (than in Australia and Thailand) (13). Specifically in the context of abscess development, diabetic tissue macrophages impair *B. pseudomallei* killing capacity and an impaired interleukin IL12–interferon-γ response had been implicated (14). Conversely, melioidosis-associated deaths in patients with diabetes had decreased by 10.8% during our study period. This improvement in outcome might have found its roots in the drive for optimization of diabetes care at the public health level in Singapore in recent years (15).

Conclusions

The overall death rate from melioidosis in Singapore was 18.4%, similar to that in the Northern Territory of Australia (14%). In both locations, these rates were attained on the background of similar standards and accessibility to healthcare and a low threshold for institution of treatment for melioidosis in accordance with recommendations (7). As efforts continue to further optimize clinical outcomes in acute melioidosis, our experience from Singapore for 2003–2014 suggests that acquisition of melioidosis and pneumonia may be curtailed through enhanced environmental and water management incorporating countrywide infrastructural improvements. In addition, enhanced management of the at-risk cohort of persons with diabetes also might prove pivotal in reducing disease.

L.Y.A.C. has been supported by the Clinician Scientist Award (CSA), Individual Research Grant, Bedside & Bench grants, and the Training Fellowship Award from the National Medical Research Council, Singapore. He also acknowledges the Aspiration Grant, Bench to Bedside Grant and Seed Funding Grant from National University Health System, Singapore. A.R.C. received funding support from the Communicable Disease Public Health Research Grant number CDPHRG12NOV021.

L.Y.A.C. has received grant support and has been advisor/consultant for Pfizer and Merck Sharp and Dohme, Gilead, and Astellas.

Mr. Pang is a biostatistician at the Saw Swee Hock School of Public Health, National University of Singapore. His primary research interests include infectious diseases epidemiology and modeling.

References


Address for correspondence: Louis Yi Ann Chai, Division of Infectious Diseases, University Medicine Cluster, National University Health System, NUHS Tower Block, 1E Kent Ridge Rd, Singapore 119228, Singapore; email: chailouis@hotmail.com